Cancer
BCR/ABL 210 kD fusion protein 259-269 (HLA-A*03:01) (HLA-A*11:01)
€105.00*
Prices excl. VAT plus shipping
costs
Available, delivery time:
3 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
95% HPLC-MS
Caution:
For research use only. Not for use in humans.
Amount in mg
1
Product number: EP11088_1
Description
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed BCR-ABL 210 kD fusion protein-derived peptide of ATGFKQSSK sequence covering 259-269 and A*03:01, A*11:01 molecule.
TechData
| Sequence: | ATGFKQSSK |
| Gene: | BCR |
| Delivery: | 3 weeks |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Human Bcr-abl 210 kD fusion protein |
| Species: | Human |
| Allele: | HLA-A*03:01, HLA-A*11:01 |
| Application: | Flow Cytometry |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |